Cboe (CBOE) Q3 2026 Earnings Call Transcript

Cboe (CBOE) reported Q3 2026 net revenue of $712M, up 18% YoY, and adjusted EPS of $3.63, up 36%. The company extended its S&P Dow Jones Indices licensing agreement to 2051 and received approval for securities-based KPI contracts on 23 companies. Derivatives business grew 22%, driven by index options and retail engagement.

Original reporting
Published Oct 30, 2026, 6:43 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 6:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Cboe (CBOE) Q3 2026 Earnings Call Transcript — source image
Decision brief

The 30-second read

$CBOEBullishMed
01

Why it matters

The earnings beat and long‑term partnership extension provide a clear growth narrative, likely supporting the stock in the short term.

02

Market read

CBOE's earnings and partnership news are material for traders focused on financial‑services and derivatives stocks.

03

What to watch

Potential regulatory scrutiny on new KPI contracts and the impact of rising volatility on VIX product revenues.

Relevance 8/10Novelty 8/10Timing: after market close

Background

CBOE is a leading U.S. options exchange that recently extended its exclusive licensing agreement with S&P Dow Jones Indices through 2051 and launched new KPI contracts.

Company-level read

Ticker impact

$CBOEBullishHigh confidence
Context

CBOE reported Q3 2026 results with 18% revenue growth to $712M and EPS $3.63, plus a 25‑year licensing extension with S&P Dow Jones.

Expected impact

likely upward pressure as investors price in revenue growth and long‑term licensing revenue.

Evidence & confidence

Revenue beat expectations and a multi‑decade partnership extension provide a clear growth catalyst.

Market effects

Boosts confidence in the options and derivatives sector, highlighting continued demand for index products.

Positive for US equity markets, especially firms tied to exchange‑listed derivatives.

Reinforces the global appeal of SPX‑based products and may influence international brokers' offerings.

Counterpoint

If the market had already priced in strong growth, the results may be a modest confirmation rather than a catalyst.

Key entities

  • CBOE Global Markets, Inc.

    U.S.-listed exchange operator reporting Q3 2026 results.

  • S&P Dow Jones Indices

    Provider of the index licensing agreement extended for 25 years.

Related articles

$CBOEMed

CFTC turns Cboe’s own words against it in stock perpetuals lawsuit

The CFTC allowed stock perpetual futures to proceed, then faced a lawsuit from the Capital Markets Alliance (Cboe, Citadel Securities, Healthy Markets Association). The CFTC's defense uses Cboe's past statements and product designs, arguing inconsistency in classification. The alliance's structure and location are also questioned. The case hinges on whether these products are security futures or swaps.

$CMEMed

Trump administration’s embrace of "perp" futures sets off risk alarms for Wall Street stalwarts

The Trump administration's push for perpetual futures (perps) in the US has raised concerns among traditional exchanges like CME Group and Cboe Global Markets, which argue the products are misclassified as futures and pose new risks. Perps, popular in crypto markets, trade 24/7 and can be highly leveraged. The CFTC approved US-listed crypto perps in May, and last week approved single-stock equity perps, sparking lawsuits from incumbent exchanges.

$CBOEMed

Cboe, Citadel Securities and Healthy Markets Sue CFTC Over Stock Perpetuals

Cboe, Citadel Securities, and Healthy Markets sued the CFTC over its approval of perpetual derivatives tied to individual US stocks, arguing they should be classified as security-based swaps under SEC oversight. A judge questioned the CFTC's authority but denied an emergency halt. The case involves KalshiEX, Bitnomial Exchange, and Coinbase Derivatives, with a preliminary injunction request pending.

$CBOEMed

Cboe and Citadel Securities-backed industry body contests CFTC green light for single-stock perpetual derivatives

The Capital Markets Alliance (CMA), backed by Cboe and Citadel Securities, sued the CFTC over its approval of single-stock perpetual derivatives. The CMA argues these products should fall under SEC jurisdiction and that the CFTC violated the Administrative Procedure Act. The CMA seeks to vacate the approvals, but a judge denied an emergency restraining order, indicating the CMA may succeed in its claim. The CFTC and CMA are set to respond by November 6 and 10, respectively.

$CBOEMed

Cboe and Citadel Securities Are Suing to Overturn the CFTC’s Approval of Stock Perpetual Futures. Could That Slow Hyperliquid?

Cboe Global Markets (CBOE) and Citadel Securities sued to overturn the CFTC's approval of stock perpetual futures, which Hyperliquid (HYPE) lists outside the U.S. The lawsuit aims to classify these contracts as security-based swaps and halt trading. HYPE's token is trading at $86, down 1.3% in 24 hours but up 7.4% in a week. The lawsuit could impact U.S. exchanges like Coinbase (COIN) and Bitnomial, while Hyperliquid's offshore operations may face fewer competitors in the short term.

$CBOELow

Analysis: Cboe, Citadel Securities backed group sues CFTC over stock perpetuals

The Capital Markets Alliance (CMA), backed by Cboe and Citadel Securities, sued the CFTC to halt perpetual futures trading on individual US stocks, arguing they should be classified as security-based swaps. The CFTC approved the contracts, but the CMA claims they should require SEC registration for retail sales. The lawsuit also questions the CFTC's approval process, which automatically approved the products after 45 days without objection.